Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Gross Margin (2020 - 2025)

Insight Molecular Diagnostics' Gross Margin history spans 6 years, with the latest figure at 53.46% for Q3 2025.

  • For Q3 2025, Gross Margin rose 998.0% year-over-year to 53.46%; the TTM value through Sep 2025 reached 54.73%, up 5078.0%, while the annual FY2024 figure was 39.34%, 1186.0% up from the prior year.
  • Gross Margin for Q3 2025 was 53.46% at Insight Molecular Diagnostics, down from 67.57% in the prior quarter.
  • Across five years, Gross Margin topped out at 67.57% in Q2 2025 and bottomed at 401.49% in Q3 2022.
  • The 5-year median for Gross Margin is 25.57% (2024), against an average of 8.5%.
  • The largest annual shift saw Gross Margin soared 921953bps in 2021 before it crashed -31348bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 134.07% in 2021, then surged by 101bps to 1.74% in 2022, then plummeted by -2247bps to 37.26% in 2023, then soared by 207bps to 40.04% in 2024, then surged by 34bps to 53.46% in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Gross Margin are 53.46% (Q3 2025), 67.57% (Q2 2025), and 61.97% (Q1 2025).